HIV Treatment Starts Faster in Chongqing, But Gaps Persist, Five-Year Study Finds

Starting antiretroviral therapy within days of an HIV diagnosis has become one of the most powerful tools in modern HIV medicine, and a new population-based study from Chongqing, China, offers one of the clearest pictures yet of how quickly that ideal is becoming reality. Researchers at the Chongqing Center for Disease Control and Prevention analyzed the records of 34,271 newly diagnosed HIV/AIDS patients aged 18 and older between 2021 and 2025, drawing on the National Integrated AIDS Prevention and Control Information System. Their findings, published in BMC Infectious Diseases, show meaningful progress toward rapid treatment initiation alongside stubborn disparities that leave certain groups waiting far longer than others.

The study defined rapid antiretroviral therapy, or ART, as treatment beginning within seven days of diagnosis. Over the full study period, 40.3 percent of newly diagnosed patients achieved that benchmark. That figure may appear modest, but the trajectory tells a more encouraging story. The median interval between diagnosis and treatment fell from 13 days in 2021, with an interquartile range of 6 to 30 days, to just 7 days by 2025, with an interquartile range of 2 to 14 days. Statistical testing confirmed that the year-over-year rise in rapid initiation rates was highly significant, with a P value below 0.001.

The clinical logic behind rapid initiation is well established. Early suppression of viral replication preserves immune function, reduces the risk of opportunistic infections, and lowers the concentration of circulating virus that can be transmitted to sexual partners. International guidelines have progressively moved toward same-day or near-same-day treatment offers, and China’s national response has followed a similar direction. What has been harder to establish is how these policy shifts translate into practice across large, diverse populations, and which patients consistently fall through the cracks. The Chongqing dataset, one of the largest of its kind, addresses precisely that gap.

Using multivariate logistic regression, the researchers identified a distinct profile of patients who were more likely to start treatment quickly. Those diagnosed in 2024 or 2025 had markedly higher odds of rapid initiation than those diagnosed earlier in the study window, reflecting the cumulative effect of system-level improvements. Women, married individuals, and those who were divorced or widowed were more likely to begin therapy within a week than unmarried men. Higher educational attainment and HIV acquisition through homosexual transmission were also associated with faster starts, as was the prescription of modern integrase-inhibitor-based regimens combining bictegravir with emtricitabine and tenofovir alafenamide.

On the other side of the ledger, several factors predicted delays. Patients who were not local residents of Chongqing were less likely to initiate treatment rapidly, a finding that points to the friction created when people are diagnosed away from their registered place of residence and must navigate cross-regional care coordination. Individuals infected through injection drug use or other transmission routes also faced longer waits, as did patients identified through medical institutions rather than through dedicated testing programs. Perhaps most tellingly, those who did not receive a baseline CD4 cell count test were significantly less likely to start therapy within seven days, suggesting that incomplete diagnostic workups translate directly into treatment delays.

Each of these determinants carries operational significance. The association between baseline CD4 testing and rapid initiation underscores how tightly coupled laboratory infrastructure is to treatment speed in practice. A patient whose immune status is not promptly assessed may be routed into additional appointments, referrals, or administrative steps before a prescription is finalized. Conversely, the strong performance of patients receiving bictegravir, emtricitabine, and tenofovir alafenamide regimens reflects the broader shift toward simplified, tolerable, once-daily combinations that clinicians can prescribe with fewer pre-treatment barriers, since these agents carry fewer drug interactions and less demanding monitoring requirements than older alternatives.

The disparities linked to marital status, education, and transmission route likely reflect a combination of health literacy, social support, and engagement with the healthcare system. Married and partnered individuals may have family members who encourage prompt follow-up, while higher education correlates with better navigation of medical bureaucracy. Men who acquired HIV through homosexual transmission, a group that in China is often reached through community-based testing organizations with strong linkage-to-care networks, may simply arrive at diagnosis already connected to services. By contrast, patients diagnosed opportunistically in hospitals, often after symptoms have already developed, may face more complex clinical situations that complicate immediate treatment decisions.

The finding that non-local residents experience slower initiation is particularly relevant for a megacity like Chongqing, which serves a highly mobile population of migrant workers. China’s HIV care system has historically been organized around household registration, and although national policies have moved toward portability of treatment, practical barriers remain, including insurance enrollment, record transfers, and unfamiliarity with local clinics. The study’s authors argue that strengthening cross-regional care coordination is one of the key levers for closing the gap, alongside integrated testing-diagnosis-treatment services, targeted health education, and continued simplification of ART regimens.

Methodologically, the study leverages the strengths of a population-based retrospective cohort design. Rather than sampling patients from a single clinic, the researchers captured essentially the entire population of newly diagnosed adults recorded in the national surveillance system within the municipality over five years, which minimizes selection bias and makes the findings representative of real-world practice in the region. The analytical approach combined descriptive statistics, chi-square tests for group comparisons, Cochran-Armitage trend tests to formally evaluate the time trend, and multivariate logistic regression to isolate the independent contribution of each determinant. The research was approved by the Medical Ethics Committee of the Chongqing Center for Disease Control and Prevention, and because it involved secondary analysis of anonymized surveillance data, the requirement for individual informed consent was waived.

The study does have the limitations inherent to surveillance data, including reliance on recorded variables and the absence of clinical outcomes such as viral suppression or retention in care, which future work should link to initiation speed. Even so, the implications are clear. Chongqing has cut its median diagnosis-to-treatment interval roughly in half in five years, and nearly half of the remaining patients now start therapy within a week, but a majority still do not. The researchers conclude that consolidating the gains will require treating the pathway from a positive test to a first prescription as a single, seamless service rather than a chain of separate steps, and directing resources toward the subgroups, migrants, people who inject drugs, and patients diagnosed in medical settings, for whom that pathway remains slowest. As other regions in China and beyond pursue the UNAIDS goal of ending AIDS as a public health threat, the Chongqing experience demonstrates both that rapid initiation at scale is achievable and that equity must be engineered into the system deliberately rather than assumed to follow automatically.

Subject of Research: Rapid antiretroviral therapy initiation among newly diagnosed people living with HIV in Chongqing, China

Article Title: Trends and determinants of rapid antiretroviral therapy initiation among newly diagnosed people living with HIV in Chongqing, China: a population-based study, 2021–2025

Article References: Tan, B., Bai, C., Fei, L., Lin, J., He, Y., Li, L., Tan, T., & Zhou, C. (2026). Trends and determinants of rapid antiretroviral therapy initiation among newly diagnosed people living with HIV in Chongqing, China: a population-based study, 2021–2025. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14606-7

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14606-7

Keywords: HIV, antiretroviral therapy, rapid ART initiation, Chongqing, China, public health, epidemiology, CD4 testing, health disparities, BMC Infectious Diseases, treatment linkage, surveillance data